A carregar...

Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma

The hepatocyte growth factor/c-MET pathway has been implicated in the pathobiology of multiple myeloma, and c-MET inhibitors induce myeloma cell apoptosis, suggesting that they could be useful clinically. We conducted a phase II study with the c-MET inhibitor tivantinib in patients with relapsed, or...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ann Hematol
Main Authors: Baljevic, Muhamed, Zaman, Shadia, Baladandayuthapani, Veerabhadran, Lin, Yan Heather, de Partovi, Claudia Morales, Berkova, Zuzana, Amini, Behrang, Thomas, Sheeba K., Shah, Jatin J., Weber, Donna M., Fu, Min, Cleeland, Charles S., Wang, Xin Shelley, Stellrecht, Christine M., Davis, Richard E., Gandhi, Varsha, Orlowski, Robert Z.
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Berlin Heidelberg 2017
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5406425/
https://ncbi.nlm.nih.gov/pubmed/28337527
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00277-017-2980-3
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!